Conclusions : CETP inhibitors are not associated with an increased risk of MACE or all-cause mortality .
There is a trend towards small reductions in nonfatal MI and cardiovascular death , though the clinical importance of such reductions is likely modest
Background : Cholesteryl ester transfer protein ( CETP ) inhibitors increase serum high-density lipoprotein cholesterol ( HDL-c ) concentration ; however , their impact on cardiovascular outcomes is not clear .
This systematic review examines the effect of CETP inhibitors on serum lipid profiles , cardiovascular events , and all-cause mortality .
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
Aims Co- primary objectives were to evaluate dalcetrapib ( JTT-705/RO4607381 ) , which targets cholesteryl ester transfer protein ( CETP ) , effects on high-density lipoprotein cholesterol ( HDL-C ) in participants with coronary heart disease or risk equivalents and to evaluate potential changes in mesenteric lymph nodes . Methods and results Double-blind trial with participants r and omized ( 2:1 ) to dalcetrapib 900 mg/day ( higher than 600 mg phase III dose ) or placebo , both with atorvastatin  , for 24 weeks ( n = 135 ; one without post-baseline efficacy data was excluded from intent-to-treat population ) ; a subset continued for 24-week extension ( n = 77 ) . Lipid changes and safety parameters were assessed . Mesenteric lymph nodes were evaluated by magnetic resonance imaging . Dalcetrapib  increased HDL-C ( 33.4 % , Week 24 ; 33.8 % , Week 48 ) , decreased CETP activity ( –53.5 % , Week 24 ; –56.5 % , Week 48 ) , and increased apolipoprotein A-I ( 11.4 % , Week 24 ; 16.4 % , Week 48 ) . Dalcetrapib showed no clinical ly relevant differences vs. placebo  in adverse events , laboratory parameters including aldosterone , electrocardiograms , and vital signs including blood pressure ( BP ) .  Dalcetrapib had no measurable , clinical ly relevant effect on lymph node size . Conclusion Dalcetrapib 900 mg administered for up to 48 weeks showed no clinical ly relevant changes in lymph nodes , BP , or other safety parameters . Dalcetrapib effectively increased HDL-C over 48 weeks of treatment
Conclusions : CETP inhibitors are not associated with an increased risk of MACE or all-cause mortality .
There is a trend towards small reductions in nonfatal MI and cardiovascular death , though the clinical importance of such reductions is likely modest
Background : Cholesteryl ester transfer protein ( CETP ) inhibitors increase serum high-density lipoprotein cholesterol ( HDL-c ) concentration ; however , their impact on cardiovascular outcomes is not clear .
This systematic review examines the effect of CETP inhibitors on serum lipid profiles , cardiovascular events , and all-cause mortality .